ArticleJournal of neuroinflammation2026
Estrogen deprivation exacerbates Alzheimer's disease pathology through neuronal CTSS signaling.
Article in Journal of neuroinflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Alzheimer's disease (AD) exhibits a pronounced sex bias, with women facing disproportionately higher risk and more severe pathology. Postmenopausal estrogen decline is implicated in this vulnerability, yet the molecular mechanisms linking estrogen loss to AD pathogenesis remain incompletely understood. Here, we demonstrate that ovariectomy (OVX) in female 5xFAD mice significantly exacerbates amyloid-β (Aβ) pathology, cognitive deficits, neuroinflammation, and reduces synaptic markers. Pharmacological blockade of estrogen receptor signaling recapitulated these effects, confirming their dependence on estrogen receptor pathways. Single-nucleus RNA sequencing (snRNA-seq) revealed widespread transcriptional reprogramming across brain cell types following estrogen deprivation, with prominent upregulation of the lysosomal protease cathepsin S (Ctss) and the AD risk gene ApoE. Remarkably, partial genetic reduction of CTSS prevented OVX-induced Aβ accumulation, glial activation, and synaptic decline in female 5xFAD mice, establishing CTSS as a critical downstream mediator of estrogen deficiency-driven pathology. Our findings provide mechanistic insight into sex-biased AD vulnerability and identify CTSS as a promising therapeutic target for mitigating AD risk in postmenopausal women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.